AUTHORS
Priyanshi Maurya, MBBS, Mohamed Doma, MD2, Varshini Srinivasan, MBBS3, Vishnu Sudhakaran, MD4, Sukul Khanna5, Adham Ramadan, MD6, Ayesha Laraib, MBBS7, Sawsan El sweilmein, MD8, Indraneel Deshmukh, MD, MPH9, Osama Mosalem, MD10, Furha Cossor, MD11
AFFILIATIONS
1 University of Missouri - Kansas City, Kansas City, Missouri, United States
2 Massachusetts General Hospital, Boston, United States
3 University of Missouri - Kansas City, Kansas City, Missouri, United States
4 University of Missouri - Kansas City, Kansas City, Missouri, United States
5 University of Missouri - Kansas City, Kansas City, Missouri, United States
6 Boston Medical Center, Boston, United States
7 University of Missouri - Kansas City, Kansas City, Missouri, United States
8 University of Missouri - Kansas City, Kansas City, Missouri, United States
9 Willis Knighton, Shreveport, United States
10 Saint Luke's Cancer Institute, Kansas City, United States
11 Saint Luke's Cancer Institute, Kansas City, United States
ABSTRACT
Introduction: CD19-directed chimeric antigen receptor T-cell (CAR-T) and CD20×CD3 bispecific antibodies are both established treatments for refractory or relapsed diffuse large B-cell lymphoma (DLBCL). CAR-T produces more frequent and higher-grade cytokine release syndrome (CRS) than the bispecifics, raising the concern of increased cardiovascular events. Existing comparative studies have reported efficacy and general toxicity but have not evaluated their cardiovascular endpoints. This study aims to assess cardiovascular events of both treatments leveraging a large administrative database.
Methods: Using the TriNetX Global Collaborative Network, we identified first cohort including adults with DLBCL who received CD19 CAR-T (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) but never received bispecific antibodies and a second cohort with adults with DLBCL who received a CD20×CD3 bispecific (epcoritamab, glofitamab) but never received CAR-T after their DLBCL diagnosis (2021–2024), as immune-effector therapy. The index event was the first administration of the assigned treatment modality. Propensity-score matching was done on demographics, cardiovascular and metabolic comorbidities, prior anthracycline and rituximab exposure, corticosteroid use, LVEF and renal function. Incident outcomes were assessed over 365 days: new-onset heart failure, arrhythmia (atrial fibrillation/flutter, ventricular fibrillation/flutter), myocardial infarction, stroke/TIA, and all-cause mortality. Risk differences, risk ratios, and Kaplan-Meier hazard ratios were assessed.
Results: After matching, 484 patients were included in both arms (all standardized differences <0.1; matched mean age 68 years, 62% male, heart failure 16%, prior anthracycline 25%). All-cause mortality was lower after CAR-T than bispecific therapy (26.7% vs 35.7%; HR 0.63, 95% CI 0.50-0.79; p<0.001). Additionally, new-onset heart failure (5.1% vs 7.3%; HR 0.62, 95% CI 0.35-1.10; p=0.10), arrhythmias (5.0% vs 5.8%; HR 0.76, p=0.66), myocardial infarction (3.0% vs 2.8%; HR 0.96, p=0.45), and stroke (3.2% vs 3.2%; p=0.40) did not statistically differ between groups.
Conclusions: In propensity-matched patients with relapsed/refractory DLBCL, CD19 CAR-T was associated with lower all-cause mortality than CD20×CD3 bispecific antibodies, while incident heart failure, arrhythmia, myocardial infarction, and stroke were comparable over one year. Despite CAR-T's greater CRS intensity, there was no observed difference in cardiovascular events.
DISCLOSURES
Priyanshi Maurya, MBBS: No relevant conflicts of interest to declare.